Skip to content
drillr.ai

STOK

Stoke Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$27.68-4.72%

Price as of Jul 20, 2026

STOK news

Stoke Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Stoke Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&esheet=54571932&newsitemid=20260716006460&lan=en-US&anchor=Stoke+Therapeutics%2C+Inc.&index=1&md5=d03481a9f9e015280157831383c86d8f) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigat

    Business Wire ·

  2. Stoke Therapeutics to Present at Upcoming Investor Conferences in June

    Stoke Therapeutics to Present at Upcoming Investor Conferences in June Stoke Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&esheet=54543631&newsitemid=20260528090671&lan=en-US&anchor=Stoke+Therapeutics%2C+Inc.&index=1&md5=df18630c9eb64e284399f491eb108797) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicin

    Business Wire ·

  3. Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Stoke Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&esheet=54485595&newsitemid=20260408281696&lan=en-US&anchor=Stoke+Therapeutics%2C+Inc.&index=1&md5=9c971e444d4d8f9a485aa9746706a060) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investig

    Business Wire ·

  4. The Credibility Filter Wall Street Uses to Sort Biotech Winners

    VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data([1]). That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines([2]). It’s becoming apparent that smart money is no longer ch

    Globe Newswire ·

  5. Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Stoke Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&esheet=54481458&newsitemid=20260407803400&lan=en-US&anchor=Stoke+Therapeutics%2C+Inc.&index=1&md5=7c7fe34c1ee361f617558ee43361d478) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medici

    Business Wire ·

  6. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome –Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– Stoke Therapeutics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&esheet=54438737&news

    Business Wire ·